, Volume 68, Issue 5, pp 653–689 | Cite as


A Review of its Use in the Management of Major Depressive Disorder
  • Sohita Dhillon
  • Lily P. H. Yang
  • Monique P. Curran
Adis Drug Evaluation



Bupropion is presumed to be a dopamine-norepinephrine reuptake inhibitor and is n effective antidepressant. It is available as three oral formulations: (i) bupropion immediate release (IR) [Wellbutrin®] administered three times daily; (ii) bupropion sustained release (SR) [Wellbutrin SR®] administered twice daily; and (iii) bupropion extended/modified release (XR) [Wellbutrin XL®/Wellbutrin XR®] administered once daily. All three formulations are bioequivalent in terms of systemic exposure to bupropion.

Oral three-times-daily bupropion IR was effective and generally well tolerated in the treatment of major depressive disorder (MDD). It was as efficacious and as well tolerated as some tricyclic antidepressants (TCAs) and the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Moreover, it was associated with less somnolence and weight gain than some TCAs. Twice-daily bupropion SR was also efficacious and generally well tolerated in the treatment of MDD. It was as effective as and had a generally similar tolerability profile to some SSRIs, but had the advantage of less somnolence and sexual dysfunction. The efficacy of bupropion XR in terms of primary efficacy measures was established in two of six well designed placebo-controlled studies. Bupropion XR also demonstrated efficacy in terms of some secondary outcomes in five of these studies. Additionally, bupropion XR was similar, in terms of the primary efficacy outcomes, to the SSRI escitalopram in two placebo-controlled trials and to the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release (XR) in two trials (one of which was placebo-controlled), but not in a third placebo-controlled trial where venlafaxine XR was better than bupropion XR. It was generally as well tolerated as escitalopram and venlafaxine XR, but was associated with less sexual dysfunction than escitalopram. Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.

Pharmacological Properties

As with all antidepressants, the precise mechanism of action of bupropion in MDD is unknown, although bupropion selectively inhibits dopamine and norepinephrine reuptake. The reuptake inhibition potential of bupropion is greater for dopamine than for norepinephrine. Importantly, bupropion does not affect serotonergic pathways and does not act on postsynaptic histamine, α- or β-adrenergic, dopamine or acetylcholine receptors.

Time to reach maximum plasma concentration (Cmax) varied between bupropion formulations (IR ≈2 h, SR ≈3 h and XR ≈5 h). A decreased number of peak plasma levels were associated with bupropion SR and XR, compared with bupropion IR. However, bioequivalent systemic exposure (as assessed by Cmax and area under the plasma concentration-time curve) was established between all formulations of bupropion and its three pharmacologically active metabolites. Steady state is reached within 8 days. Bupropion is extensively metabolized, mainly by cytochrome P450 (CYP) isoenzymes or via carbonyl reduction. As the active metabolites of bupropion reach higher steady-state concentrations than those of bupropion, these metabolites may be of clinical importance. Bupropion has an elimination half-life (t½) of 20–21 hours and is predominantly (87%) excreted in the urine as metabolites. The t½ of the active metabolites of bupropion are ≈20, ≈33 and ≈37 hours. There is potential for drug-drug interactions between bupropion and drugs that affect CYP2B6 and 2D6 metabolism, drugs that are substrates of these isoenzymes and drugs that affect metabolism in general.

Therapeutic Efficacy

Three-times-daily bupropion IR was effective in the treatment of MDD in a 6-week randomized, double-blind clinical trial in adults with moderate to severe disease, demonstrating greater improvement from baseline in several efficacy measures relative to placebo. Moreover, bupropion IR was as effective as the SSRI fluoxetine, the TCAs nortriptyline, amitriptyline and doxepin, and the atypical antidepressant trazodone in reducing symptoms of depression and anxiety assessed by several efficacy measures in 6- to 13-week trials in adults with MDD.

Similarly, twice-daily bupropion SR was effective in the treatment of MDD in 8-week, randomized, double-blind clinical trials in adults with moderate to severe disease, demonstrating greater improvements from baseline in several efficacy measures relative to placebo. In addition, bupropion SR was effective in preventing relapse in one 52-week relapse-prevention study in a similar patient population. In comparative trials, there were no significant differences between bupropion SR and the SSRIs sertraline or fluoxetine in adults and the SSRI paroxetine in elderly patients with moderate to severe disease in randomized studies of 6- to 16-weeks' duration. Furthermore, bupropion SR was as effective as the SSRI sertraline and the SNRI venlafaxine XR with respect to remission rates (primary efficacy measure) in patients who were switched from citalopram therapy because of a lack of remission of symptoms or because they could not tolerate citalopram in the large, randomized, multicentre STAR*D trial. In the same study, bupropion SR was shown to be as effective as the serotonin receptor agonist buspirone, in terms of remission rates, when used to augment citalopram therapy in a similar patient population. There were some benefits with bupropion SR relative to buspirone therapy as demonstrated by a greater reduction from baseline in self-rated 16-item Quick Inventory of Depressive Symptomology (QIDS-SR-16) score and a lower QIDS-SR-16 score with bupropion compared with buspirone therapy at study end.

Two of six placebo-controlled trials in adult and elderly patients with moderate to severe MDD demonstrated greater improvements from baseline in the 30-item self-rated Inventory of Depressive Symptomology scale or Montgomery-Åsberg Depression Rating Scale (MADRS) total scores (primary efficacy measures) with once-daily bupropion XR relative to placebo. However, in the trial involving elderly patients, although significant reduction from baseline in MADRS total scores in bupropion XR relative to placebo recipients in the last-observation-carried-forward analysis (primary efficacy measure) was not observed, significant improvements from baseline were observed in the protocol-defined observed-case or per-protocol analyses and according to the rank analysis of covariance and robust regression analysis. Benefit with respect to some secondary measures was observed with bupropion XR relative to placebo in five of six placebo-controlled efficacy studies in adults and the elderly.

There were no significant differences between bupropion XR and the SSRI escitalopram in terms of the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score (primary efficacy measure) in patients with moderate to severe disease in placebo-controlled studies of 8 weeks' duration. Similarly, in two 8- and 12-week studies, one of which was placebo-controlled, in patients with similar disease, there were no significant differences between bupropion XR and the SNRI venlafaxine in terms of primary (MADRS total score) or secondary (HAM-D-17 total score) efficacy measures. Additionally, in the 12-week study, more patients achieved remission with bupropion XR than venlafaxine XR therapy. However, in one 8-week placebo-controlled study, venlafaxine XR was better than bupropion XR in terms of MADRS total scores (primary efficacy measure).


All three formulations of bupropion (IR, SR or XR) were generally well tolerated in patients with moderate to severe MDD. Adverse event-related withdrawal rates in pooled analyses were 5–11 % in bupropion IR, SR or XR recipients. Overall, the most common treatment-emergent adverse events reported in bupropion IR, SR or XR versus placebo recipients were headache (20–26% vs 20–23%), dry mouth (16–28% vs 7–18%) and nausea (13–23% vs 8–19%); agitation was another common treatment-emergent adverse event reported in 32% of bupropion IR compared with 22% of placebo recipients. Bupropion SR and XR were also well tolerated in terms of their effects on sexual functioning in patients with MDD.

Most adverse events associated with bupropion SR or XR relative to placebo were mild to moderate in severity. However, there is a dose-dependent risk of seizures (0.4% with bupropion IR 300–450 mg/day; 0.1% with bupropion SR 100–300 mg/day, increasing to 0.4% with bupropion SR 400 mg/day; and 0.1% with bupropion XR ≤450 mg/day) associated with the use of bupropion. Although the effect of bupropion (IR, SR or XR) on suicidality is not clear, it is recommended that patients should be monitored closely. In general, the effects of bupropion (IR, SR or XR) on vital signs (systolic and diastolic blood pressure and heart rate) were small, although some changes (largely an increase in ≤12% of patients) in these parameters with bupropion XR were of potential concern or were sustained (in 3–11% of patients) during therapy.

Although the tolerability profile of bupropion (IR, SR or XR) was generally similar to that of TCAs (nortriptyline, amitriptyline and doxepin), an atypical antidepressant (trazodone), SSRIs (including sertraline, fluoxetine and escitalopram) and an SNRI (venlafaxine XR) in patients with moderate to severe MDD, some adverse events were reported in fewer bupropion than comparator recipients.

Bupropion SR and XR were associated with less sexual dysfunction than SSRIs, such as sertraline and escitalopram. Bupropion XR had a more favourable effect on sexual function than venlafaxine XR in one study, which assessed the parameter as the primary outcome measure, but not in two others where sexual function was assessed as a secondary outcome measure. Bupropion IR and SR were associated with less somnolence relative to some TCAs and SSRIs. On the other hand, the incidence of dry mouth was higher with bupropion IR and SR than with some SSRIs, but lower than that observed with some TCAs. In patients receiving citalopram therapy augmented with bupropion SR or buspirone in the STAR*D trial, discontinuation rates due to intolerance were lower with bupropion SR plus citalopram than with buspirone plus citalopram.

Although bupropion IR, SR and XR were associated with a weight gain of >2.3 kg (>5 lb), the incidence of weight gain was ≈4-fold lower with bupropion IR than with TCAs. Bupropion (IR, SR or XR) was also associated with a weight loss of >2.3 kg (>5 lb). However, the incidence of weight loss with bupropion IR was approximately twice that observed with TCAs. No clinically significant changes in weight were observed in bupropion SR or placebo recipients after 52 weeks of therapy.


Major Depressive Disorder Bupropion Escitalopram Immediate Release Primary Efficacy Measure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders. Fourth edition, text revisions. Washington, DC: American Psychiatric Association, 2000: 345–428CrossRefGoogle Scholar
  2. 2.
    Holtzheimer III PE, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006 Jan; 3(1): 42–56PubMedCrossRefGoogle Scholar
  3. 3.
    Kessler RC, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289(23): 3095–105PubMedCrossRefGoogle Scholar
  4. 4.
    Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 109 Suppl. 4: 21–7CrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr; 157 Suppl. 4: 1–45Google Scholar
  6. 6.
    Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60 Suppl. 4: 4–11PubMedGoogle Scholar
  7. 7.
    GlaxoSmithKline. Wellbutrin (bupropion hydrochloride): US prescribing information [online]. Available from URL: http:// [Accessed 2008 Jan 15]Google Scholar
  8. 8.
    GlaxoSmithKline. Wellbutrin SR (bupropion hydrochloride sustained-release tablets): US prescribing information [online]. Available from URL: 2007/020358s0431bl.pdf [Accessed 2008 Jan 15]Google Scholar
  9. 9.
    GlaxoSmithKline. Wellbutrin XL (bupropion hydrochloride extended-release): US prescribing information [online]. Available from URL: 021515s0201bl.pdf [Accessed 2008 Jan 15]Google Scholar
  10. 10.
    Heads of Medicines Agencies. Wellbutrin XR: summary of product characteristics [online]. Available from URL: http:// [Accessed 2008 Mar 4]Google Scholar
  11. 11.
    Fava M, Rush AJ, Thase ME, et al. 15 Years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7(3): 106–13PubMedCrossRefGoogle Scholar
  12. 12.
    Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004; 6(4): 159–66PubMedCrossRefGoogle Scholar
  13. 13.
    Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998 Dec; 51(3): 237–54PubMedCrossRefGoogle Scholar
  14. 14.
    Argyelan M, Szabo Z, Kanyo B, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-l SPECT study. J Affect Disord 2005 Dec; 89(1–3): 115–23PubMedCrossRefGoogle Scholar
  15. 15.
    Meyer JH, Goulding VS, Wilson AA, et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002 Aug; 163(1): 102–5CrossRefGoogle Scholar
  16. 16.
    Learned-Coughlin SM, Bergström M, Savitcheva I, et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 2003 Oct 15; 54(8): 800–5PubMedCrossRefGoogle Scholar
  17. 17.
    Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 2004 Sep; 66(3): 675–82PubMedCrossRefGoogle Scholar
  18. 18.
    Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999 Jan; 288(1): 88–92PubMedGoogle Scholar
  19. 19.
    Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006 Dec 15; 60(12): 1350–5PubMedCrossRefGoogle Scholar
  20. 20.
    Johnston JA, Ascher J, Leadbetter R, et al. Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation. Drugs 2002; 62 Suppl. 2: 11–24PubMedCrossRefGoogle Scholar
  21. 21.
    Ott GE, Rao U, Lin KM, et al. Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response. Int J Neuropsychopharmacol 2004 Sep; 7(3): 275–81PubMedCrossRefGoogle Scholar
  22. 22.
    Ott GE, Rao U, Nuccio I, et al. Effect of bupropion-SR on REM sleep: relationship to antidepressant response. Psychopharmacology (Berl) 2002 Dec; 165(1): 29–36CrossRefGoogle Scholar
  23. 23.
    Nofzinger 3rd EA, Reynolds CF, Thase ME, et al. REM sleep enhancement by bupropion in depressed men. Am J Psychiatry 1995 Feb; 152(2): 274–6PubMedGoogle Scholar
  24. 24.
    Kast RE. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry 2003 Nov–Dec 31; 25(6): 495–6PubMedCrossRefGoogle Scholar
  25. 25.
    Modell JG, Boyce S, Taylor E, et al. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med 2002 Sep–Oct; 64(5): 835–40PubMedCrossRefGoogle Scholar
  26. 26.
    Kast RE, Altschuler EL. Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion [letter]. J Hepatol 2003 Jul; 39(1): 131–3PubMedCrossRefGoogle Scholar
  27. 27.
    Altschuler EL, Kast RE. Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-α? [letter]. Psychosom Med 2003 Jul–Aug; 65(4): 719PubMedCrossRefGoogle Scholar
  28. 28.
    Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion [letter]. Gastroenterology 2001 Nov; 121(5): 1260–1PubMedCrossRefGoogle Scholar
  29. 29.
    Vane SV, Altschuler EL, Kast RE. Crohn's disease remission on bupropion [letter]. Gastroenterology 2003 Oct; 125(4): 1290CrossRefGoogle Scholar
  30. 30.
    Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007 May; 16(5): 474–84PubMedCrossRefGoogle Scholar
  31. 31.
    Heads of Medicines Agencies. Public assessment report of the Medicines Evaluation Board in the Netherlands [online]. Available from URL: [Accessed 2008 Mar 4]Google Scholar
  32. 32.
    GlaxoSmithKline. Steady-state bioequivalence evaluation of bupropion sustained-release and bupropion immediate-release tablets in healthy male volunteers (study no. 206) [online]. Available from URL: [Accessed 2008 Jan15]Google Scholar
  33. 33.
    Golden RN, De Vane CL, Laizure SC, et al. Bupropion in depression (II): the role of metabolites in clinical outcome. Arch Gen Psychiatry 1988 Feb; 45(2): 145–9PubMedCrossRefGoogle Scholar
  34. 34.
    GlaxoSmithKline. A two-way, crossover, steady state, multiple-dose, open-label, fasting, comparative bioavailability study of bupropion HCl 300mg extended release tablets (1 X 300mg q.d.) versus Wellbutrin 100mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects (study no. AK1BIOVAIL2543) [online]. Available from URL: http:// [Accessed 2008 Jan 15]Google Scholar
  35. 35.
    Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995 Sep; 35(9): 876–84PubMedGoogle Scholar
  36. 36.
    Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003 Oct; 13(10): 619–26PubMedCrossRefGoogle Scholar
  37. 37.
    Pollock BG, Sweet RA, Kirshner M, et al. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996 Oct; 18(5): 581–5PubMedCrossRefGoogle Scholar
  38. 38.
    Odishaw J, Chen C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 2000 Dec; 20(12): 1448–53PubMedCrossRefGoogle Scholar
  39. 39.
    Hogeland GW, Swindells S, McNabb JC, et al. Lopinavir/ ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007 Jan; 81(1): 69–75PubMedCrossRefGoogle Scholar
  40. 40.
    Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 82–4PubMedGoogle Scholar
  41. 41.
    Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005 Nov; 27(11): 1685–95PubMedCrossRefGoogle Scholar
  42. 42.
    Bryant SG, Guernsey BG, Ingrim NB. Review of bupropion. Clin Pharm 1983 Nov–Dec 31; 2(6): 525–37PubMedGoogle Scholar
  43. 43.
    Davidson JRT, Connor KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry 1998; 59 Suppl. 4: 25–31PubMedGoogle Scholar
  44. 44.
    Hewett K, Chrzanowski W, Rousseau R, et al. Efficacy and safety of bupropion XL in elderly patients with major depressive disorder [abstract no. P.2.C.006 plus poster]. Eur Neuropsychopharmacol 2006; 16 Supl. 4: S315–16Google Scholar
  45. 45.
    Thase ME, Clayton AH, Chrzanowski W, et al. Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials [abstract no. 146 plus poster]. 14th Congress of Psychiatry of the Association of European Psychiatrists; 2006 Mar 4–8; NiceGoogle Scholar
  46. 46.
    Mendels J, Amin MM, Chouinard G, et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 1983 May; 44 (5 Pt 2): 118–20PubMedGoogle Scholar
  47. 47.
    Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 1990 May; 51(5): 194–9PubMedGoogle Scholar
  48. 48.
    Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991 Aug; 52(8): 329–35PubMedGoogle Scholar
  49. 49.
    Reimherr FW, Cunningham LA, Batey SR, et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients. Clin Ther 1998 May 30; 20: 505–16PubMedCrossRefGoogle Scholar
  50. 50.
    Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun; 14(3): 170–9PubMedCrossRefGoogle Scholar
  51. 51.
    Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec; 58(12): 532–7PubMedCrossRefGoogle Scholar
  52. 52.
    Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec; 11(4): 205–15PubMedGoogle Scholar
  53. 53.
    Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr; 21(4): 643–58PubMedCrossRefGoogle Scholar
  54. 54.
    Coleman CC, King BR, Bolden-Watson C, et al. A placebocontrolled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001 Jul; 23(7): 1040–58PubMedCrossRefGoogle Scholar
  55. 55.
    Weihs Jr KL, Settle EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000 Mar; 61(3): 196–202PubMedCrossRefGoogle Scholar
  56. 56.
    Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry 2002 May 1; 51(9): 753–61PubMedCrossRefGoogle Scholar
  57. 57.
    Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Jun; 67(6): 865–73PubMedCrossRefGoogle Scholar
  58. 58.
    Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006 May; 67(5): 736–46PubMedCrossRefGoogle Scholar
  59. 59.
    Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006 Oct; 26(5): 482–8PubMedCrossRefGoogle Scholar
  60. 60.
    Masco HL, Kiev A, Holloman LC, et al. Safety and efficacy of bupropion and nortriptyline in outpatients with depression. Curr Ther Res 1994; 55(7): 851–63CrossRefGoogle Scholar
  61. 61.
    Feighner J, Hendrickson G, Miller L, et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J Clin Psychopharmacol 1986 Feb; 6(1): 27–32PubMedCrossRefGoogle Scholar
  62. 62.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1231–42PubMedCrossRefGoogle Scholar
  63. 63.
    Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 Mar 23; 354(12): 1243–52PubMedCrossRefGoogle Scholar
  64. 64.
    Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001 Oct; 62(10): 776–81PubMedCrossRefGoogle Scholar
  65. 65.
    Dunner DL, Kwong WJ, Houser TL, et al. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Prim Care Companion J Clin Psychiatry 2001 Feb; 3(1): 10–6PubMedCrossRefGoogle Scholar
  66. 66.
    GlaxoSmithKline. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible-dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg–300mg once daily), extended-release venlafaxine hydrochloride (75mg–150mg once daily) and placebo in subjects with major depressive disorder (study no. AK130939) [online]. Available from URL: [Accessed 2007 Dec 18]Google Scholar
  67. 67.
    GlaxoSmithKline. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg–300mg once daily), extended-release venlafaxine hydrochloride (75mg–150mg once daily) and placebo in subjects with major depressive disorder (study No. WXL101497) [online]. Available from URL: [Accessed 2007 Dec 18]Google Scholar
  68. 68.
    GlaxoSmithKline. A twelve-week, multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled, escalating dose study to compare the effects on sexual functioning of bupropion hydrochloride extended-release (WELLBUTRIN®XL, 150–450 mg/day) and extended-release venlafaxine (Effexor XR, 75–225 mg/day) in subjects with major depressive disorder (study No. WELL 100368) [online]. Available from URL: [Accessed 2007 Dec 18]Google Scholar
  69. 69.
    Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005 Aug; 66(8): 974–81PubMedCrossRefGoogle Scholar
  70. 70.
    Croft HA, Wightman D, Hewett K, et al. Additional data on the safety and tolerability of bupropion extended-release: newly accumulated data extends previous findings in placebo controlled clinical trials [abstract no. NR484 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON)Google Scholar
  71. 71.
    Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999 Mar; 21(3): 454–63PubMedCrossRefGoogle Scholar
  72. 72.
    Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991 Nov; 52(11): 450–6PubMedGoogle Scholar
  73. 73.
    Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001 Dec; 35(12): 1608–13PubMedCrossRefGoogle Scholar
  74. 74.
    Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000 Apr; 20(2): 122–8PubMedCrossRefGoogle Scholar
  75. 75.
    Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002 Apr; 63(4): 357–66PubMedCrossRefGoogle Scholar
  76. 76.
    Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007 Jul; 21(5): 461–71PubMedCrossRefGoogle Scholar
  77. 77.
    National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical practice guideline 23. London: National Institute for Clinical Excellence, 2004Google Scholar
  78. 78.
    Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 May; 184: 386–92PubMedCrossRefGoogle Scholar
  79. 79.
    Mann JJ. The medical management of depression. N Engl J Med 2005; 353(17): 1819–34PubMedCrossRefGoogle Scholar
  80. 80.
    Papakostas GI. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram [commentary]. Evid Based Ment Health 2006 Nov; 9(4): 100PubMedCrossRefGoogle Scholar
  81. 81.
    Stang P, Suppapanaya N, Hogue SL, et al. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther 2007 May–Jun 30; 14(3): 241–6PubMedCrossRefGoogle Scholar
  82. 82.
    McLaughlin T, Hogue SL, Stang PE. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression. Am J Ther 2007 Mar–Apr 30; 14(2): 221–5PubMedCrossRefGoogle Scholar
  83. 83.
    Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008 Jan 17; 358(3): 252–60PubMedCrossRefGoogle Scholar
  84. 84.
    Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 Feb; 5(2): e45PubMedCrossRefGoogle Scholar
  85. 85.
    Settle ECJ. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998; 59 Suppl. 4: 32–6PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Sohita Dhillon
    • 1
    • 2
  • Lily P. H. Yang
    • 1
    • 2
  • Monique P. Curran
    • 1
    • 2
  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, 0754, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations